ARTICLE | Finance
Perceptive-backed LianBio readies for its next act
After $325M IPO, seven deals, and addition of a China GM, cross-border play prepares to start pivotal studies
November 4, 2021 1:31 AM UTC
With a new CEO and GM of China, nine in-licensed therapies and a $325 million IPO under its belt, LianBio is poised to start registrational trials of three assets next year, including lead therapy mavacamten.
LianBio (NASDAQ:LIAN) raised $325 million via the sale of 20.3 million ADSs at $16, the mid-point of its range for a postmoney valuation of $1.7 billion. Goldman Sachs, Jefferies, BofA Securities and Raymond James underwrote the deal. ...